Want to join the conversation?
$AET and $MRK entered into unique value-based contract that supports objectives to help adult patients with type 2 diabetes access appropriate treatment. $MRK's rebates on Januvia and Janumet will be based in part on products' contributions to help $AET's commercial member population with type 2 diabetes achieve or maintain treatment objectives.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.